, 2013). This previous microarray includes gp160 subtype consensus sequences from six HIV-1 group M subtypes (A, B, C, D, CRF_01 and CRF_02) and a consensus group M gp160, Con-S. In contrast to the global microarray reported here, this previous microarray contains less than a quarter of the number of peptides (1423 vs. Cell Cycle inhibitor 6564), excludes variable sequences by design, and does not include any non-Env proteins, making it potentially less optimal for quantifying HIV-1 antibody epitope diversity. Given the density of peptides on the microarray (19,692 peptides over 3 triplicate sub-arrays), we designed a program to evaluate the quality of raw microarray data following sample

incubation and immunolabeling, as described above. Fig. 3 demonstrates representative results of this analysis following microarray

incubation with plasma from an HIV-1-infected subject. As shown in this example, the program provides a snapshot of how well the results from each sub-array correlate with each other; in this case the correlation ranged from R2 = 0.93 to 0.96. We also designed a program to determine a threshold value above which a signal can be considered GW3965 concentration “positive” (Renard et al., 2011). Fig. 4 demonstrates representative results of this analysis when the microarray was incubated with plasma from an HIV-1-infected subject. By providing four potential threshold values with varying stringency, the program allows the user to decide whether his or her analysis will have greater sensitivity or specificity in detecting antibody binding. The goal of this project was to develop a method to both quantitate and visualize antibody binding patterns to diverse HIV-1 sequences for the purpose of HIV-1 vaccine and therapeutic research. To visualize binding patterns, one Galeterone can plot the magnitude of peptide binding (MFI) by peptide location (starting amino acid position). For instance, Fig. 5A demonstrates the gp140-specific binding pattern among HIV-1-infected subjects, where the average MFI per peptide is shown for the 5 subjects. In this example, peak MFI values were observed at the V3 region of gp120

and the CC loop region of gp41, with maximum values about 60,000 MFI, consistent with well-described immunodominant regions in HIV-1 infection (Goudsmit, 1988, Tomaras et al., 2008, Tomaras and Haynes, 2009 and McMichael et al., 2010). Among HIV-uninfected controls, there were a handful of nonspecific positive peptides, but peak values did not rise above 4500 MFI (Fig. 5B). For comparison, Fig. 5C shows the binding pattern among human subjects vaccinated with a single priming dose of Ad26-EnvA HIV-1 vaccine. Here peak binding values were observed to V1, V2 and V3 linear peptides, with maximum MFIs up to about 12,000. The lower MFI of vaccinees compared to HIV-1-infected subjects is expected given receipt of only one dose of vaccine without subsequent boosting, but were still above those observed in naïve controls (Fig. 5D).